8-K: Citius Pharma Launches LYMPHIR, Reports FY25 Results

Citius Pharmaceuticals announced the U.S. launch of its cancer immunotherapy LYMPHIR and reported fiscal year 2025 financial results, including a net loss of $39.7 million.

Summary

• Citius Pharma's subsidiary, Citius Oncology, launched LYMPHIR (denileukin diftitox-cxdl) in the U.S. in December 2025 for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy.
• LYMPHIR is the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018, targeting an initial market estimated to exceed $400 million.
• The company secured distribution agreements with three leading U.S. pharmaceutical wholesalers and access in 19 international markets through named patient programs.
• LYMPHIR received a Category 2A recommendation in the National Comprehensive Cancer Network (NCCN) guidelines and a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) to aid in obtaining coverage and reimbursement.
• Citius Pharma raised approximately $25 million and Citius Oncology raised $36 million in gross proceeds from strategic financings, totaling approximately $61 million.
• For the fiscal year ended September 30, 2025, the net loss was $39.7 million, or ($3.38) per share, compared to a net loss of $40.2 million, or ($5.97) per share, for the prior fiscal year.
• Cash and cash equivalents increased to $4.3 million as of September 30, 2025, from $3.3 million in the prior year.
• Research and development expenses decreased to $9.2 million for fiscal year 2025 from $11.9 million for fiscal year 2024.
• The company continues to engage with the FDA regarding next steps for its late-stage pipeline candidates, Mino-Lok and Halo-Lido, with Mino-Lok having met primary and secondary endpoints in its Phase 3 trial.

Sentiment

Score: 7

Explanation: The successful launch of LYMPHIR, a first-in-class therapy for an underserved market, is a major positive. The significant capital raises provide funding for commercialization. While the company remains unprofitable, this is expected for a biopharma in this stage, and the slight improvement in net loss per share is encouraging. The strong commercialization efforts and pipeline progress contribute to a positive outlook despite ongoing financial burn.

Positives

• Successful U.S. launch of LYMPHIR in December 2025, marking the first new systemic therapy for CTCL patients since 2018.
• LYMPHIR targets an initial market estimated to exceed $400 million, which is growing and underserved by existing therapies.
• Secured inclusion of LYMPHIR in NCCN guidelines with a Category 2A recommendation and a permanent HCPCS J-code (J9161), significantly aiding coverage and reimbursement.
• Established robust commercial infrastructure, including distribution agreements with three leading U.S. pharmaceutical wholesalers and access in 19 international markets via named patient programs.
• Ensured production and sufficient supply of LYMPHIR for up to 18 months of estimated commercial demand.
• Raised approximately $61 million in gross proceeds from strategic financings ($25 million for Citius Pharma, $36 million for Citius Oncology), strengthening the financial foundation.
• Net loss per share improved to ($3.38) in fiscal year 2025 from ($5.97) in fiscal year 2024.
• Cash and cash equivalents increased to $4.3 million as of September 30, 2025, from $3.3 million in the prior year.
• Mino-Lok met primary and secondary endpoints in its pivotal Phase 3 trial, indicating progress in the late-stage pipeline.

Negatives

• Reported a net loss of $39.7 million for fiscal year 2025, indicating continued unprofitability.
• No revenues were reported for the fiscal year ended September 30, 2025, as the company is in the pre-commercialization phase for its primary revenue-generating products.
• General and administrative expenses slightly increased to $18.5 million in fiscal year 2025 from $18.2 million in fiscal year 2024.
• Inventory significantly increased to $22.3 million as of September 30, 2025, from $8.3 million in the prior year, tying up capital for product supply.
• Accounts payable increased substantially to $13.7 million as of September 30, 2025, from $4.9 million in the prior year.

Risks

• Need for substantial additional funds and the ability to raise additional money to fund operations for at least the next 12 months as a going concern.
• Ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream.
• Uncertainty regarding the estimated markets for LYMPHIR and product candidates and their acceptance by any market.
• Ability to secure strategic partnerships and expand international access to LYMPHIR.
• Ability to use the latest technology to support commercialization efforts for LYMPHIR.
• Physician and patient acceptance of LYMPHIR in a competitive treatment landscape.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations.
• Ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR.
• Risks relating to the results of research and development activities, including those from existing and any new pipeline assets.
• Ability to procure cGMP commercial-scale supply.
• Ability to obtain, perform under, and maintain financing and strategic agreements and relationships.
• Ability to maintain Nasdaq's continued listing standards.
• Patent and intellectual property matters.
• Ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis.
• Government regulation.
• Impact of any future public health risks.

Future Outlook

Citius Pharma is focused on the successful launch and adoption of LYMPHIR in 2026, with even greater opportunities ahead to drive value for patients and shareholders. The company is actively engaging with the FDA to advance Mino-Lok, exploring additional indications and markets for LYMPHIR, and working diligently to strengthen its financial and operational foundation to support sustained growth. Management anticipates reporting on continued progress in the coming months.

Management Comments

• "2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018."
• "This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with limited options."
• "With LYMPHIR commercially available as of December 2025, we are focused on its successful launch and adoption in 2026, with even greater opportunities ahead to drive value for patients and shareholders."
• "We are actively engaging with the FDA to advance Mino-Lok, exploring additional indications and markets for LYMPHIR, and working diligently to strengthen our financial and operational foundation to support sustained growth."
• "We look forward to reporting on our continued progress in the coming months."

Industry Context

The launch of LYMPHIR marks a significant development in the treatment landscape for cutaneous T-cell lymphoma (CTCL), being the first new systemic therapy since 2018. This addresses a growing and underserved market estimated to exceed $400 million. The inclusion in NCCN guidelines and securing a permanent HCPCS J-code are critical steps for market penetration and reimbursement, positioning LYMPHIR favorably against existing, older therapies. The company's strategy to expand international access via named patient programs and leverage AI for sales and marketing indicates a modern, aggressive approach to commercialization in the competitive oncology space.

Stakeholder Impact

• Shareholders: Potential for increased value due to the successful launch of LYMPHIR and its market potential, but also continued dilution from capital raises and ongoing losses.
• Patients: Access to a new systemic therapy (LYMPHIR) for relapsed or refractory Stage I-III CTCL, the first since 2018, offering a new treatment option for an underserved population.
• Employees: Continued employment and potential growth opportunities within Citius Pharma and Citius Oncology as commercialization efforts expand.
• Healthcare Providers: New treatment option (LYMPHIR) for CTCL patients, supported by NCCN guidelines and a dedicated J-code for easier prescribing and reimbursement.
• Distributors/Partners: Engagement with leading U.S. pharmaceutical wholesalers and international distribution partners for LYMPHIR, creating new business opportunities.

Next Steps

• Focus on successful launch and adoption of LYMPHIR in 2026.
• Actively engage with the FDA to advance Mino-Lok.
• Explore additional indications and markets for LYMPHIR.
• Work diligently to strengthen financial and operational foundation to support sustained growth.
• Report on continued progress in the coming months.

Key Dates

Recommendation

The successful launch of LYMPHIR is a significant positive, addressing an underserved market and providing a clear path to potential revenue generation. The substantial capital raised provides a runway for commercialization. However, the company remains pre-revenue for its products, continues to incur significant losses, and faces substantial risks related to market acceptance, reimbursement, and competition. While the long-term potential is promising, the immediate financial performance and execution risks warrant a 'hold' recommendation, advising investors to monitor the initial commercial uptake of LYMPHIR and further pipeline developments before making a more aggressive move.

Keywords

Citius Pharmaceuticals, CTXR, Citius Oncology, CTOR, LYMPHIR, denileukin diftitox-cxdl, CTCL, Cutaneous T-cell Lymphoma, Cancer Immunotherapy, FDA Approval, Biopharmaceutical, Mino-Lok, Halo-Lido, Financial Results, Drug Launch, Orphan Drug, Oncology